Rolapitant

• UNSPSC Description:

  Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model[1][2].

• Target Antigen:

  Neurokinin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Rolapitant.html

• Solubility:

  DMSO : ≥ 30 mg/mL

• Smiles:

  C[C@@](C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)([H])OC[C@@]2(C3=CC=CC=C3)CC[C@@](CCC4=O)(N4)CN2

• Molecular Weight:

  500.48

• References & Citations:

  [1]Duffy RA, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokininNK1 receptor antagonist with centrally-mediated antiemetic effects inferrets. Pharmacol Biochem Behav. 2012 Jul;102(1):95-100.|[2]Rapoport B, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015 Nov;23(11):3281-8.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  552292-08-7